Tempus AI Drives R&D with Multiple Product Launches
Tempus AI is advancing precision medicine by rolling out a series of innovative products and platforms. In June, the company introduced xM, a liquid biopsy assay designed to detect molecular responses to immune-checkpoint inhibitor therapy in advanced solid tumors. Currently available only for research, clinical availability is expected later this year.
Earlier, in May, Tempus AI launched its Fuses program. This initiative aims to accelerate the company’s testing capabilities by expanding its AI-powered diagnostics portfolio, creating new opportunities for patient care and research insights.
April saw the debut of Tempus Loop, an oncology-focused platform for target discovery and validation. Loop combines real-world patient data with human biological models and CRISPR screens, leveraging AI to expedite the identification of novel targets for preclinical therapeutic development.
Starting the year, Tempus AI released olivia, an AI-enabled personal health concierge app that centralizes health data and delivers actionable insights to patients. Alongside olivia, the company introduced xT CDx, an FDA-approved next-generation sequencing (NGS) in vitro diagnostic device. This 648-gene test profiles solid tumors, assessing microsatellite instability and including companion diagnostic claims for colorectal cancer.
Looking ahead, Tempus AI is developing xH, its first whole-genome sequencing test. This marks a significant expansion into comprehensive genomic profiling, particularly aimed at improving personalized therapy in hematological oncology by detecting all clinically relevant variants.
Industry Peers Also Push Product Innovation
Veracyte has made notable progress with its product pipeline. In April, it introduced the Decipher Prostate metastatic test in a limited release, with a full roll-out planned for June. This test broadens Decipher’s coverage across prostate cancer stages, helping guide treatment plans and avoid unnecessary chemotherapy. Veracyte also plans updates to its Afirma test in mid-2025 and aims to launch the Prosigna breast cancer test in the US by 2026. Additionally, the company is progressing on the Percepta Nasal Swab test for lung cancer risk.
Myriad Genetics continues to develop new tests and improve existing ones. Last year, it launched the Prequel Prenatal Screen, which provides critical insights at eight weeks gestation, earlier than previous offerings. Myriad also introduced the Foresight Carrier Screening test with an expanded gene panel and enhanced workflows. Early access has been given for the FirstGene assay, combining carrier screening and noninvasive prenatal testing. The company’s first AI-enabled Prolaris test supports clinical decisions at biopsy, developed in partnership with OMIC.
Tempus AI Stock Performance and Valuation
Tempus AI shares have risen 83.6% over the past year, outperforming the industry’s 38% growth and the S&P 500’s 12.3% increase. The stock currently trades at a forward 12-month Price-to-Sales ratio of 7.50X, higher than the industry average of 5.88X.
Outlook on Earnings Estimates
Earnings projections for Tempus AI in 2025 and 2026 are mixed. The stock carries a Zacks Rank #4 (Sell), reflecting cautious sentiment from analysts despite the company’s product momentum.
Your membership also unlocks:
